Patient demographic data and baseline disease characteristics by conversion to ACPA and RF seronegative status at month 6
| Conversion to ACPA seronegative status | Persistent ACPA seropositive | Conversion to RF seronegative status | Persistent RF seropositive | |||||
| Abatacept+MTX (n=15) | MTX alone (n=6) | Abatacept+MTX (n=212) | MTX alone (n=202) | Abatacept+MTX (n=39) | MTX alone (n=22) | Abatacept+MTX (n=191) | MTX alone (n=209) | |
| Age, years | 50.7 (11.1) | 61.2 (11.4) | 49.8 (12.3) | 48.8 (12.7) | 51.6 (10.3) | 49.5 (14.4) | 49.6 (12.6) | 49.7 (12.8) |
| Female, n (%) | 13 (86.7) | 6 (100) | 157 (74.1) | 159 (78.7) | 29 (74.4) | 18 (81.8) | 145 (75.9) | 170 (81.3) |
| Weight, kg | 65.6 (17.0) | 68.8 (16.6) | 72.3 (17.8) | 72.7 (17.9) | 71.2 (17.2) | 68.1 (16.1) | 71.9 (18.3) | 73.5 (18.1) |
| Race, white, n (%) | 14 (93.3) | 4 (66.7) | 167 (78.8) | 173 (85.6) | 34 (87.2) | 20 (90.9) | 147 (77.0) | 179 (85.6) |
| Region, n (%) | ||||||||
| North America | 2 (13.3) | 0 | 40 (18.9) | 27 (13.4) | 9 (23.1) | 3 (13.6) | 32 (16.8) | 34 (16.3) |
| South America | 5 (33.3) | 0 | 83 (39.2) | 87 (43.1) | 7 (17.9) | 9 (40.9) | 88 (46.1) | 88 (42.1) |
| Europe | 7 (46.7) | 4 (66.7) | 72 (34.0) | 75 (37.1) | 20 (51.3) | 8 (36.4) | 56 (29.3) | 74 (35.4) |
| ROW | 1 (6.7) | 2 (33.3) | 17 (8.0) | 13 (6.4) | 3 (7.7) | 2 (9.1) | 15 (7.9) | 13 (6.2) |
| Duration of RA, months | 8.9 (8.8) | 1.7 (1.5) | 6.0 (7.4) | 7.0 (7.1) | 3.7 (5.0) | 6.9 (8.0) | 7.1 (8.0) | 7.0 (7.1) |
| Tender joints | 30.0 (16.2) | 20.3 (6.9) | 31.1 (14.9) | 30.3 (13.7) | 24.6 (14.3) | 29.8 (15.0) | 32.9 (15.1) | 30.9 (14.0) |
| Swollen joints | 23.2 (10.3) | 15.8 (7.6) | 22.9 (11.7) | 22.4 (10.4) | 20.9 (9.6) | 20.4 (10.1) | 23.7 (11.9) | 22.4 (10.4) |
| Patient pain assessment | 62.5 (25.5) | 56.6 (27.4) | 67.2 (22.2) | 66.8 (22.5) | 64.6 (24.9) | 61.4 (22.3) | 67.9 (22.4) | 67.6 (22.8) |
| HAQ-DI | 1.4 (0.7) | 1.7 (0.6) | 1.7 (0.7) | 1.7 (0.7) | 1.6 (0.5) | 1.7 (0.6) | 1.7 (0.7) | 1.7 (0.7) |
| Patient global assessment, 100 mm VAS | 61.7 (25.7) | 50.3 (28.2) | 66.3 (21.3) | 64.3 (23.6) | 67.5 (22.0) | 61.5 (22.9) | 65.4 (22.6) | 63.7 (24.3) |
| Physician global assessment, 100 mm VAS | 59.4 (16.3) | 56.7 (17.4) | 67.9 (18.2) | 65.4 (19.1) | 64.1 (18.5) | 61.9 (16.0) | 68.2 (18.3) | 66.1 (19.4) |
| DAS28 (CRP) | 6.2 (0.9) | 5.9 (0.7) | 6.3 (1.0) | 6.3 (1.0) | 6.1 (0.9) | 6.0 (1.1) | 6.4 (1.0) | 6.3 (1.0) |
| DAS28 (ESR) | 7.2 (0.6) | 6.2 (0.7) | 6.9 (1.0) | 6.7 (1.1) | 6.7 (0.8) | 6.4 (1.3) | 6.9 (1.0) | 6.8 (1.1) |
| ESR, mm/hour | 44.4 (18.0) | 55.5 (34.3) | 49.5 (28.8) | 49.8 (32.9) | 48.5 (21.3) | 41.2 (24.3) | 49.4 (29.9) | 51.1 (32.7) |
| CRP, mg/dL | 2.4 (2.0) | 4.7 (3.4) | 3.3 (3.3) | 3.8 (5.4) | 3.0 (3.0) | 2.6 (3.2) | 3.2 (3.1) | 3.8 (5.4) |
| Baseline RF positive, n (%) | 14 (93.3) | 6 (100) | 204 (96.2) | 197 (97.5) | 39 (100) | 22 (100) | 191 (100) | 209 (100) |
| Baseline RF titre, IU/mL | 267.2 (465.0) | 192.2 (214.5) | 323.8 (481.4) | 297.6 (359.3) | 61.9 (84.5) | 39.2 (36.1) | 369.0 (503.5) | 306.7 (352.2) |
| Baseline ACPA positive, n (%) | 15 (100) | 6 (100) | 212 (100) | 202 (100) | 34 (87.2) | 15 (68.2) | 179 (93.7) | 185 (88.5) |
| Baseline ACPA titre, AU/mL | 18.6 (29.8) | 9.0 (2.2) | 347.9 (558.9) | 323.7 (546.2) | 202.7 (291.3) | 143.8 (226.0) | 341.3 (585.0) | 292.8 (543.4) |
| TSS | 7.1 (8.7) | 15.4 (17.1) | 7.7 (9.8) | 6.7 (8.6) | 6.6 (10.6) | 5.7 (5.9) | 7.6 (9.3) | 6.5 (8.6) |
| JSN score | 2.5 (4.6) | 5.8 (9.7) | 2.1 (4.1) | 1.8 (3.9) | 2.0 (4.8) | 1.5 (2.5) | 2.1 (3.9) | 1.9 (4.1) |
| Erosion score | 4.6 (5.0) | 9.6 (8.1) | 5.6 (6.3) | 4.9 (5.5) | 4.6 (6.2) | 4.2 (3.9) | 5.5 (6.1) | 4.6 (5.2) |
Data are mean (SD) unless stated otherwise. Conversion to ACPA or RF seronegative status at month 6 meant that patients who were ACPA or RF seropositive at baseline, respectively, became seronegative at month 6; persistent ACPA or RF seropositive meant that patients were ACPA or RF seropositive at both baseline and at month 6.
ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; JSN, joint space narrowing; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; ROW, rest of world; TSS, total Sharp score; VAS, visual analogue scale.